Nutriband Inc. Warrant closed at $1.66 on Sep 28, up 26.72%, 36.8% below its highest close since Oct 1. Volume of 45.5K shares was 6.75× its 20-day average (well above normal).
Split-adjusted performance: +137.1% over one month.
In the quarter ended Jul 31, 2026, revenue was $437.51K, down 29.7% from a year earlier, with a net margin of -201.3%.
Short interest was 4.3K shares at the Sep 15 settlement, up 144.1% from the prior report (1.0 days to cover).
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids.
What is NTRBW's market cap?
$1.25M, based on the Sep 28 close of $1.66.
What sector is NTRBW in?
Healthcare, in the Orthopedic & Surgical Supplies industry.
About Nutriband Inc. Warrant
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
HQ: Orlando, FL3 employeesListed Oct 1, 2021nutriband.com
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
